Program

CONCURRENT EDUCATION SESSIONS

2:00 p.m.-4:15 p.m. 

• EDUCATION SESSION 1: CANCER BIOLOGY AND CANCER MEDICINE: A PRIMER FOR GENOMIC SCIENTISTS
  

  
  What Makes Cancer So Difficult to Treat?
  Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA

  Cancer Evaluation and Treatment in the Genomic Era
  Richard L. Schilsky, University of Chicago Medical Center, Chicago, IL

• EDUCATION SESSION 2: BIOSTATISTICS AND CANCER GENOMICS: A PRIMER FOR BIOLOGISTS
  

  
  Introduction to Basic Tools for Analysis of Genomic Data
  John Q. Quackenbush, Dana-Farber Cancer Institute, Boston, MA

  Applications to Cancer Genomics
  John Q. Quackenbush

WELCOME AND OPENING KEYNOTE ADDRESS

6:00 p.m.–7:00 p.m.

Welcome

Patterns of Somatic Mutation in Human Cancer Genomes
Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, England

SESSION 1: CHALLENGES AND OPPORTUNITIES

Chairperson to be announced
7:00 p.m.-9:00 p.m.

Going Beyond p Values
Lynda Chin, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Omics and Predictive Biomarkers
Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA

Omics in Drug Development
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

Biomarkers in the Practice of Medicine
Richard L. Schilsky, University of Chicago Medical Center, Chicago, IL

OPENING RECEPTION

9:00 p.m.-10:30 p.m.

KEYNOTE ADDRESS II

8:15 a.m.-9:00 a.m.

Recurrent Gene Fusions in Prostate Cancer: A New Class of Biomarkers and Therapeutic Targets
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

SESSION 2: CONVERTING DATA INTO HYPOTHESES

Chairperson: John Q. Quackenbush, Dana-Farber Cancer Institute, Boston, MA
9:00 a.m.-11:00 a.m.

Knowledge-based Methods for Cancer Genomics Studies
Jill P. Mesirov, Broad Institute, Cambridge, MA

Converting Genomic Data into Hypotheses
Cameron W. Brennan, Memorial Sloan-Kettering Cancer Center, New York, NY

From Expression Profiling to Putative Master Regulators
Terence P. Speed, University of California, Berkeley, CA

Stochasticity and Networks in Genomic Data
John Q. Quackenbush

SESSION 3: HIGH-THROUGHPUT BIOLOGY: IN VITRO FUNCTIONAL GENETIC SCREEN

Chairperson: Joan S. Brugge, Harvard Medical School, Boston, MA
12:30 p.m.-2:30 p.m.

Genome-scale Cancer Biology with RNAi Cell Arrays
Olli-P. Kallioniemi, VTT Technical Research Center of Finland, Turku, Finland

Functional Genomics, Experimental Models and Cancer
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Chemical Genetics: Finding Targets for Drugs
John Tallarico, Novartis Institutes for BioMedical Research, Cambridge, MA

Short talks from proffered abstracts

SESSION 4: HIGH-THROUGHPUT BIOLOGY: IN VIVO FORWARD GENETIC SCREEN

Chairperson: James R. Downing, St. Jude Children's Research Hospital, Memphis, TN
3:00 p.m.-5:00 p.m.

Identification of Tumor Suppressor Genes in vivo Using RNA Interference
Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

A Conditional Transposon-based Insertional Mutagenesis System for Modeling Cancer in Mice
Nancy A. Jenkins, Institute of Molecular and Cell Biology, Singapore

Use of Zebrafish Models and Human Oncogenomics to Find New Cancer Pathways
Leonard I. Zon, Harvard Medical School, Children's Hospital, Boston, MA

Short talks from proffered abstracts

POSTER SESSION A / EXHIBITS

7:00 p.m.-9:30 p.m.

SESSION 5: MODEL SYSTEMS FOR COMPARATIVE OMICS

Chairperson: Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, England
8:00 a.m.-10:00 a.m.

Integrated Pipeline for Mass Spectrometry-Based Discovery and Confirmation of Biomarkers Demonstrated in a Mouse Model of Breast Cancer
Amanda G. Paulovich, Fred Hutchinson Cancer Research Center, Seattle, WA

Three-Dimensional Cell Culture Models of Cancer
Joan S. Brugge, Harvard Medical School, Boston, MA

Modeling and Mining Cancer Chromosomes and Transcriptomes
Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA

Short talks from proffered abstracts

SESSION 6: PRECLINICAL THERAPEUTICS

Chairperson: David Sidransky, Johns Hopkins Medical Institute, Baltimore, MD
10:30 a.m.-12:30 p.m.

Oncogenomics to Target Myeloma Cells in the Bone Marrow Milieu
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

Stress Targeted Cancer Drugs: Preclinical Studies to Help Find the Right Patients
Garth Powis, UT M. D. Anderson Cancer Center, Houston, TX

How to Define a Cancer Drug Target
Edward A. Sausville, University of Maryland, Baltimore, MD

Short talks from proffered abstracts

POSTER SESSION B / EXHIBITS

1:30 p.m.-4:00 p.m.

SESSION 7: TRANSLATIONAL MEDICINE

Chairperson: Olli-P. Kallioniemi, VTT Technical Research Center of Finland, Turku, Finland
4:00 p.m.-6:00 p.m.

Discovery of Next Generation Drug Targets and Response Markers from Human Gene Expression Data
Lajos Pusztai, UT M. D. Anderson Cancer Center, Houston, TX

Tracking Genomic Alterations in Individuals with Cancer
David Sidransky, Johns Hopkins Medical Institute, Baltimore, MD

Genomic Strategies for Personalized Cancer Therapy
Joseph R. Nevins, Duke University, Durham, NC

Short talks from proffered abstracts

KEYNOTE ADDRESS III

6:00 p.m.-6:45 p.m.

Molecular Genetics of Acute Leukemia
James R. Downing, St. Jude Children's Research Hospital, Memphis, TN

CLOSING REMARKS

6:45 p.m.-7:00 p.m.

DEPARTURE